Zoetis Announces Agreement To Acquire Basepaws, An Innovative Leader In Petcare Genetics, To Strengthen Its Portfolio Of Precision Animal Health Solutions
Acquiring Company
Zoetis
Acquired Company
Basepaws
Description
Zoetis Inc. (NYSE:ZTS) today announced an agreement to acquire Basepaws, a privately held petcare genetics company, which provides pet owners with genetic tests, analytics and early health risk assessments that can help manage the health, wellness and quality of care for their pets. The acquisition will advance Zoetis’ portfolio in the precision animal health space and will inform and shape its future pipeline of petcare innovations. Financial terms of the agreement are not being disclosed.
Quick answer
Zoetis is acquiring Basepaws, announced June 7, 2022. Zoetis is based in Parsippany, New Jersey, United States.
- How much did Zoetis pay for Basepaws?
- The deal value was not disclosed.
- What does Zoetis do?
- As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals.
- Where are Zoetis and Basepaws based?
- Zoetis is based in Parsippany, New Jersey, United States.
- Who are the decision-makers at Zoetis?
- Fundz holds 1 contact at Zoetis. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Medical and Animal Feed
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Zoetis Completes Acquisition Of Basepaws, An Innovative Leader In Petcare Genetics, To Strengthen Its Portfolio Of Precision Animal Health Solutions (June 22, 2022)
- Archimed Completes Acquisition Of Natus Medical Incorporated For $1.2 Billion Total Equity Value, $1.2B (July 21, 2022)
- U.S. Alliance Pharma Acquires U.K.-Based Lgc’S Drug Development Solutions (Dds) Business (July 13, 2022)
- 1031 Crowdfunding Acquires Memory Care And Assisted Living Portfolio In Texas And Georgia (July 6, 2022)
- Bristol Myers Squibb To Acquire Turning Point Therapeutics, A Leading Precision Oncology Company (June 3, 2022)
- Regeneron Completes Acquisition Of Checkmate Pharmaceuticals (May 31, 2022)
Who to call at Zoetis, and when
When Zoetis changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Zoetis raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Zoetis, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Zoetis. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Zoetis makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Basepaws?
Basepaws was acquired by Zoetis, based in Parsippany. The deal was reported on June 7, 2022. As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. Zoetis is publicly traded (ZTS) and operates in Biotechnology.
When did Zoetis acquire Basepaws?
Zoetis's acquisition of Basepaws was reported on June 7, 2022. Zoetis Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Basepaws do?
Basepaws is a petcare genetics company that builds early detection health risk tests based on genetic and microbiome data. Basepaws is committed to companion animal health research, and it has the world’s first at-home genetic testing platform for cats. It is privately held, operating in Health Care.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.